富士莱(301258)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301258 富士莱

已收盘 02-06 15:00:00

{"stockData":{"symbol":"301258","market":"SZ","secType":"STK","nameCN":"富士莱","latestPrice":34.25,"timestamp":1770361398000,"preClose":34.18,"halted":0,"volume":978400,"delay":0,"changeRate":0.002,"floatShares":89065000,"shares":91670000,"eps":0.8287,"marketStatus":"已收盘","change":0.07,"latestTime":"02-06 15:00:00","open":34.11,"high":34.72,"low":33.94,"amount":33664900,"amplitude":0.0228,"askPrice":34.26,"askSize":14,"bidPrice":34.25,"bidSize":4,"shortable":0,"etf":0,"ttmEps":0.8287,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":5,"adr":0,"adjPreClose":34.18,"symbolType":"stock","openAndCloseTimeList":[[1770341400000,1770348600000],[1770354000000,1770361200000]],"highLimit":37.6,"lowLimit":30.76,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":91670000,"isCdr":false,"pbRate":1.64,"roa":"--","peRate":41.329794,"roe":"3.83%","epsLYR":0.18,"committee":-0.655172,"marketValue":3140000000,"turnoverRate":0.011,"status":0,"floatMarketCap":3050000000},"requestUrl":"/m/hq/s/301258","defaultTab":"news","newsList":[{"id":"2609458563","title":"股市必读：富士莱（301258）2月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2609458563","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609458563?lang=zh_cn&edition=full","pubTime":"2026-02-06 02:34","pubTimestamp":1770316451,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，富士莱报收于34.18元，上涨0.41%，换手率1.41%，成交量1.26万手，成交额4315.37万元。董秘最新回复投资者： 钱总，您好，公司上市这么多年长期破发，请抓紧学习并购重组六条，早日让公司多元化发展，这样才能对得起长期坚守的小股东？当日关注点来自交易信息汇总：2月5日主力资金净流入104.19万元，游资积极介入，散户资金呈净流出态势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600001925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2609706613","title":"富士莱：寻找协同效应并购标的适时资本运作","url":"https://stock-news.laohu8.com/highlight/detail?id=2609706613","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609706613?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:48","pubTimestamp":1770295719,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱02月05日在投资者关系平台上答复投资者关心的问题。公司在深耕主营业务、加强研发投入，谋求内生式发展的同时，也在寻找能够与公司产生协同效应的并购标的，适时通过资本运作扩展产业布局，通过收购兼并、参股控股等方式，寻求外延并购等发展机会，实现产业资源整合，促进公司稳健发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500037515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2608595355","title":"富士莱：截至2026年1月30日股东总户数为9,742户","url":"https://stock-news.laohu8.com/highlight/detail?id=2608595355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608595355?lang=zh_cn&edition=full","pubTime":"2026-02-04 15:48","pubTimestamp":1770191290,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)02月04日在投资者关系平台上答复投资者关心的问题。投资者提问：请问2026年1月底公司股东人数是多少？富士莱回复：尊敬的投资者，您好！截至2026年1月30日股东总户数为9,742户，感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400022556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2606248330","title":"富士莱最新公告：2025年净利同比预增282.17%-296.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606248330","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606248330?lang=zh_cn&edition=full","pubTime":"2026-01-26 20:50","pubTimestamp":1769431817,"startTime":"0","endTime":"0","summary":"富士莱(301258.SZ)发布2025年度业绩预告，预计归属于上市公司股东的净利润为0.63亿元–0.65亿元，比上年同期增长282.17%–296.80%。业绩变动原因：主要产品出货量稳定增长，叠加非经常性损益约0.68亿元（主要为理财产品投资收益及公允价值变动损益）。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600033006.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2605422172","title":"富士莱：截至目前公司不存在应披露而未披露的重大资产重组事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2605422172","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605422172?lang=zh_cn&edition=full","pubTime":"2026-01-23 15:48","pubTimestamp":1769154484,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)01月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请董秘介绍一下公司在并购重组方面的未来规划？公司如何把握行业整合机遇，提升核心竞争力？富士莱回复：尊敬的投资者，您好！截至目前，公司不存在应披露而未披露的重大资产重组事项。未来，如有符合公司发展战略、有利于提升公司核心竞争力和盈利能力的并购或合作机会，公司将会在充分考虑风险因素和投资回报的基础上，进行审慎评估和决策，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300020142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2605617235","title":"富士莱：截至2026年1月20日股东总户数为10,050户","url":"https://stock-news.laohu8.com/highlight/detail?id=2605617235","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605617235?lang=zh_cn&edition=full","pubTime":"2026-01-21 16:51","pubTimestamp":1768985474,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)01月21日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截至2026年1月20日，公司股东人数有多少？富士莱回复：尊敬的投资者，您好！截至2026年1月20日股东总户数为10,050户，感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100027256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2605452351","title":"股市必读：富士莱（301258）1月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2605452351","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605452351?lang=zh_cn&edition=full","pubTime":"2026-01-21 03:25","pubTimestamp":1768937111,"startTime":"0","endTime":"0","summary":"截至2026年1月20日收盘，富士莱报收于37.28元，上涨1.0%，换手率4.25%，成交量3.79万手，成交额1.42亿元。董秘最新回复投资者： 尊敬的董秘您好，关注到公司此前曾布局小核酸业务，但之前公开信息显示相关设备已出售、项目终止。前期购置的部分寡核苷酸中试设备因不再适应当前业务需求，公司已于2024年度对相关设备进行处置。交易信息汇总资金流向1月20日主力资金净流出122.95万元；游资资金净流出1010.33万元；散户资金净流入1133.28万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100002683.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2603151980","title":"股市必读：富士莱（301258）1月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2603151980","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603151980?lang=zh_cn&edition=full","pubTime":"2026-01-16 02:38","pubTimestamp":1768502290,"startTime":"0","endTime":"0","summary":"截至2026年1月15日收盘，富士莱报收于35.03元，上涨2.49%，换手率2.19%，成交量1.95万手，成交额6805.14万元。投资者： 以“AI+发酵+合成生物学”的落地应用，践行AI4S核心逻辑，属于AI4S在生物医药制造领域的典型产业应用案例公司有这方便的运用吗？公司密切关注AI在制药领域的应用和发展，目前暂无相关业务布局。当日关注点来自交易信息汇总：1月15日主力资金净流入825.41万元，呈现明显吸筹迹象。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600001080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2603607259","title":"富士莱：目前暂无AI在制药领域的业务布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2603607259","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603607259?lang=zh_cn&edition=full","pubTime":"2026-01-15 20:48","pubTimestamp":1768481302,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)01月15日在投资者关系平台上答复投资者关心的问题。投资者提问：以“AI+发酵+合成生物学”的落地应用，践行AI4S核心逻辑（数据与模型驱动科研生产，提升效率、缩短周期），属于AI4S在生物医药制造领域的典型产业应用案例公司有这方便的运用吗？富士莱回复：尊敬的投资者，您好！公司密切关注AI在制药领域的应用和发展，目前暂无相关业务布局。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500038639.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","301258","01477","BK1191"],"gpt_icon":0},{"id":"2603540230","title":"股市必读：富士莱(301258)股东户数0.98万户，较上期减少1.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603540230","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603540230?lang=zh_cn&edition=full","pubTime":"2026-01-13 02:08","pubTimestamp":1768241292,"startTime":"0","endTime":"0","summary":"截至2026年1月12日收盘，富士莱报收于34.34元，上涨1.21%，换手率2.24%，成交量2.0万手，成交额6799.13万元。来自股本股东变化：截至2026年1月9日股东户数环比减少1.93%，户均持股上升至9390股，筹码集中度有所提升。股本股东变化股东户数变动近日富士莱披露，截至2026年1月9日公司股东户数为9763.0户，较12月31日减少192.0户，减幅为1.93%。户均持股数量由上期的9208.0股增加至9390.0股，户均持股市值为31.86万元。截至2026年1月9日股东总户数为9,763户，感谢您对公司的关注！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300001610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2601004690","title":"富士莱：截至2025年12月31日股东总户数为9,955户","url":"https://stock-news.laohu8.com/highlight/detail?id=2601004690","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601004690?lang=zh_cn&edition=full","pubTime":"2026-01-05 17:01","pubTimestamp":1767603662,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)01月05日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，你好!请问截止至2025年12月31日，公司股东人数总数是多少?谢谢!富士莱回复：尊敬的投资者，您好！截至2025年12月31日股东总户数为9,955户，感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500023481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2593432630","title":"股市必读：富士莱（301258）12月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2593432630","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593432630?lang=zh_cn&edition=full","pubTime":"2025-12-23 02:21","pubTimestamp":1766427673,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘，富士莱报收于33.36元，上涨4.09%，换手率2.72%，成交量2.43万手，成交额8052.04万元。董秘最新回复投资者： 尊敬的董秘，您好！今天是12月中旬最后一个交易日，敬请发布截至今天公司的股东户数信息。请问截止至2025年12月19日，公司股东人数总数是多少?截至2025年12月19日股东总户数为9,810户，感谢您对公司的关注！当日关注点来自交易信息汇总：12月22日主力资金净流入493.67万元，显示主力对个股呈积极介入态势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300001318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2593210298","title":"富士莱：截至2025年12月19日股东总户数为9,810户","url":"https://stock-news.laohu8.com/highlight/detail?id=2593210298","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593210298?lang=zh_cn&edition=full","pubTime":"2025-12-22 15:42","pubTimestamp":1766389330,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)12月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，截至2025年12月20日公司的股东总数是多少？谢谢富士莱回复：尊敬的投资者，您好！截至2025年12月19日股东总户数为9,810户，感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200013001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2590982755","title":"富士莱：截至2025年12月10日股东总户数为9,811户","url":"https://stock-news.laohu8.com/highlight/detail?id=2590982755","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590982755?lang=zh_cn&edition=full","pubTime":"2025-12-11 15:51","pubTimestamp":1765439476,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，您好！敬请发布截至12月10今天收盘公司的股东户数信息。谢谢！致礼！富士莱回复：尊敬的投资者，您好！截至2025年12月10日股东总户数为9,811户，感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100020023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2590342507","title":"富士莱（301258）披露获得硫辛酸片药品注册证书，12月9日股价下跌0.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590342507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590342507?lang=zh_cn&edition=full","pubTime":"2025-12-09 22:28","pubTimestamp":1765290523,"startTime":"0","endTime":"0","summary":"截至2025年12月9日收盘，富士莱报收于32.62元，较前一交易日下跌0.67%，最新总市值为29.9亿元。该股当日开盘32.86元，最高32.99元，最低32.5元，成交额达2168.33万元，换手率为0.74%。公司近日发布公告称，苏州富士莱医药股份有限公司近日收到国家药品监督管理局签发的硫辛酸片药品注册证书，药品名称为硫辛酸片，剂型为片剂，规格为0.2g和0.6g，注册分类为化学药品3类，上市许可持有人为公司自身。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900041266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2590130173","title":"富士莱(301258.SZ)获硫辛酸片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590130173","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590130173?lang=zh_cn&edition=full","pubTime":"2025-12-09 15:55","pubTimestamp":1765266950,"startTime":"0","endTime":"0","summary":"智通财经APP讯，富士莱(301258.SZ)公告，公司近日收到国家药品监督管理局签发的关于硫辛酸片的《药品注册证书》。硫辛酸片适应症为：用于糖尿病周围神经病变引起的感觉异常。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"富士莱(301258.SZ)获硫辛酸片药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2588742709","title":"富士莱：截至2025年11月28日股东总户数为10,214户","url":"https://stock-news.laohu8.com/highlight/detail?id=2588742709","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588742709?lang=zh_cn&edition=full","pubTime":"2025-12-01 15:54","pubTimestamp":1764575649,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)12月01日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，您好！今天是11月最后一个交易日，敬请发布截至11月末公司股东户数信息。        感谢您每期都花费时间和精力回复提问。谢谢！富士莱回复：尊敬的投资者，您好！截至2025年11月28日股东总户数为10,214户，感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100013382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2586428645","title":"富士莱：瑞玞生物主营医美产品研发销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2586428645","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586428645?lang=zh_cn&edition=full","pubTime":"2025-11-25 16:31","pubTimestamp":1764059472,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)11月25日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，公司全资子公司贝格致远投资的神济昌华以及瑞玞生物分别是做什么的，两家市场前景如何。富士莱回复：尊敬的投资者，您好！公司子公司苏州贝格致远投资管理有限公司已收回对神济昌华（北京）生物科技有限公司的投资；瑞玞生物主要业务为医疗器械和化妆品系列医美产品的研发、生产和销售。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500021730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2586286244","title":"富士莱：山东项目投产将提升核心竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2586286244","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586286244?lang=zh_cn&edition=full","pubTime":"2025-11-25 16:31","pubTimestamp":1764059471,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)11月25日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，请问公司山东项目建设完成全部投产后预计可以为公司带来多少的经济效应。富士莱回复：尊敬的投资者，您好！“富士莱（山东）特色原料药及中间体CMO/CDMO建设项目”投产后将有助于提升公司在特色原料药及中间体领域的核心竞争力，为公司的可持续发展注入新动能。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500021731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2586627428","title":"富士莱：阿帕替尼原料药获GMP符合性认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2586627428","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586627428?lang=zh_cn&edition=full","pubTime":"2025-11-25 16:30","pubTimestamp":1764059458,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)11月25日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，请问公司阿帕替尼原料药项目进展如何。富士莱回复：尊敬的投资者，您好！截至目前，公司已收到江苏省药品监督管理局的药品GMP符合性检查结果告知书，获悉公司原料药甲磺酸阿帕替尼符合药品GMP，为后续的商业化奠定坚实的基础。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500021700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770500958879,"stockEarnings":[{"period":"1week","weight":0.0006},{"period":"1month","weight":0.0316},{"period":"3month","weight":-0.03},{"period":"6month","weight":-0.0905},{"period":"1year","weight":0.4378},{"period":"ytd","weight":0.0538}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1184},{"period":"1year","weight":0.243},{"period":"ytd","weight":0.0244}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"苏州富士莱医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9742人(较上一季度减少3.06%)","perCapita":"9142股","listingDate":"2022-03-29","address":"江苏省苏州市常熟市新材料产业园海旺路16号","registeredCapital":"9167万元","survey":"　　苏州富士莱医药股份有限公司的主营业务是医药中间体、原料药及保健品原料的研发、生产和销售。公司的主要产品是硫辛酸系列、磷脂酰胆碱系列、肌肽系列、艾瑞昔布。公司多年来连续被认定为“高新技术企业”。","listedPrice":48.3},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"富士莱(301258)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供富士莱(301258)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"富士莱,301258,富士莱股票,富士莱股票老虎,富士莱股票老虎国际,富士莱行情,富士莱股票行情,富士莱股价,富士莱股市,富士莱股票价格,富士莱股票交易,富士莱股票购买,富士莱股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"富士莱(301258)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供富士莱(301258)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}